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Migraine is a predominantly female disorder. Evidence
suggests that migraine activity is influenced by hormonal
factors, and particularly by estrogen levels and fluctua-
tions. During pregnancy, estrogen may reach one hundred
times the normal level, whilst progesterone levels decrease,
rising again towards the end of the pregnancy; however,
hormonal fluctuations are not as pronounced as during
the non-pregnant state [1]. Most women with migraine
report an improvement of their attacks during pregnancy,
from the first to the third trimestre, particularly women
with a history of menstrual migraine and with migraine
without aura [2]. This improvement may be due to the
lack of hormonal fluctuations but also to the increased
levels of natural pain-killing hormones (endorphins)
induced by pregnancy [1,3]. If no improvement is seen
toward the end of the first trimestre, migraine is likely to
continue throughout pregnancy and postpartum. Most
women with migraine improving in pregnancy will experi-
ence attack recurrence shortly after delivery, likely in the
first weeks [2]. This decline might be due to the precipi-
tous drop in estradiol and endorphin levels occurring in
the postpartum period [1,3]. A small number of pregnant
women experience a worsening of their migraine while a
few others may even develop de novo migraine symptoms.
In this context, migraine usually occurs during the first tri-
mestre and is most often with aura [2]. Women continu-
ing to experience migraine attacks throughout pregnancy
may require treatment but we need to consider that not
all medications used for migraine are safe in pregnancy.
Paracetamol is the preferred drug for acute treatment
throughout pregnancy. If paracetamol is not sufficiently
effective, sporadic use of sumatriptan can be considered.
NSAIDs such as ibuprofen can also be used under certain
circumstances, though their intake in the first and third
trimestres is associated with specific risks and contraindi-
cations. For prevention, non pharmacological approaches
are always first-line treatment, and should also be used to
complement any drug treatment. Some vitamins and diet-
ary supplements have been proposed, such as, magnesium,
riboflavin and coenzyme Q10. Preventive drug treatment
should only be considered in the most severe cases and
should include low doses of b-blockers and amitriptyline
[4]. A personal history of migraine headaches can affect
pregnancy outcomes. There is increasing evidence show-
ing that migraine is a risk factor for several vascular com-
plications during pregnancy, including gestational
hypertension and preeclampsia, stroke, myocardial infarc-
tion, and venous thromboembolism; therefore, migraine
should be considered a potential cardiovascular risk factor
in obstetric care[5]. Further research is warranted to
understand the mechanisms underlying the increased risk
of vascular disease in pregnant migraineurs. Better under-
standing of those mechanisms could lead to potential
treatment and earlier intervention, thereby reducing the
health care costs of morbidity and mortality associated
with adverse vascular events in this population.
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